Home Fitness Product News Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) Inks A Pact With CSCM To Develop Products...

Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) Inks A Pact With CSCM To Develop Products To Treat Health Risks And Symptoms In Patients With Diabetes And Cardiovascular Disease

24
0

Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) signed a deal with Cardiovascular Solutions of Central Mississippi (CSCM) to help patients with cardiovascular diseases and diabetes by offering innovative products. The new products developed using CBD derived from hemp and other cannabinoids exclusively for CSCM will address therapeutics needs related to patients with DPN (Diabetic Neuropathies) and PAD (Peripheral Arterial Disease).

Upfront license fee payment to Zelira

CSCM will pay an upfront license fee to Zelira. It will also pay royalties to Zelira on the commercialization of the products developed under this agreement. The company will also bear all the expenses related to marketing, manufacturing, distribution, and sale of US products.

CSCM holds exclusive marketing rights for all the products developed by Zelira as per this deal in the US markets. However, Zelira retains marketing rights for developed products in other markets across the world.

Several people are suffering from lower-limb amputations, adult blindness, and kidney failure in the US because of diabetes. According to CDC, of the 30 million Americans who have diabetes in the US, one among the three adults aged above 50 years develops PAD.

Peripheral Arterial Disease is the chief cause of non-traumatic amputations in the US. DPN, which is the most common health condition related to diabetes, is the chief cause of disability, mainly due to fall risks and foot ulcerations. If it is not cured in time, it could lead to limb amputation and infection as well.

The annual spending on diabetic treatment is $326 billion in the US. According to a recent CDC (Centers for Disease Control) projection, one in three people in the US will suffer from diabetes by the year 2050. Ethnic and racial minorities in the US usually suffer from higher health care costs.

CEO of CSCM, Dr. Foluso Fakorede, said the company is excited to enter a deal with Zelira to develop effective and innovative treatment options for patients suffering from PAD. This partnership’s main target is to develop and promote the treatment for cardiovascular disease and address unmet needs for marginalized communities.

Zelira will also focus on unveiling its HOPE Products and proprietary Zenivol in the international markets.

This content was originally published here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here